What is Dreem?
Founded in 2014, Dreem has established itself as a critical player in the digital health ecosystem. By integrating advanced hardware with rigorous scientific validation, the company provides comprehensive sleep care solutions for individuals, employers, and clinical providers. The firm's operational footprint spans New York, Paris, and Taipei, supported by a robust intellectual property portfolio of 30 patents. Dreem's commitment to clinical efficacy is evidenced by its collaborative research partnerships with prestigious institutions such as Harvard Medical School, MIT, and the Stanford Sleep Center. As a member of the Digital Therapeutics Alliance, Dreem leverages neuroscientific insights to address the growing global burden of sleep disorders, positioning itself as a leader in the intersection of medical technology and patient-centric care.
How much funding has Dreem raised?
Dreem has raised a total of $61M across 3 funding rounds:
Unspecified
$4M
Private Equity
$22M
Private Equity
$35M
Unspecified (2016): $4M with participation from Xavier Niel and Laurent Alexandre
Private Equity (2017): $22M led by Dr. Laurent Alexandre, MAIF, and Xavier Niel
Private Equity (2018): $35M supported by Bpifrance and JJDC
Key Investors in Dreem
Bpifrance
A French public investment bank that provides credit, guarantees, and equity to support innovation and international growth for startups and mid-cap companies.
JJDC
The venture capital arm of Johnson & Johnson, focusing on investments in medical technologies, pharmaceuticals, and innovative healthcare solutions that align with global health needs.
MAIF
A prominent French insurance group that diversifies its portfolio by investing in innovative companies that provide health, life, and protection solutions.
What's next for Dreem?
With the support of major strategic partners, Dreem is poised to accelerate its transition from a research-focused entity to a dominant force in enterprise-level sleep diagnostics. The current funding context suggests a strategic pivot toward broader market penetration and the scaling of its clinical-grade hardware solutions. Future initiatives will likely focus on expanding the reach of its digital therapeutics platform, enhancing its diagnostic algorithms through continued collaboration with its scientific advisory board, and deepening its integration into global healthcare systems. By maintaining its focus on scientific rigor, Dreem is well-positioned to capitalize on the increasing demand for data-driven, non-invasive sleep interventions in both clinical and corporate wellness environments.
See full Dreem company page
